



February 8, 2017

Dicerna to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in an analyst-led fireside chat at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017, at 10:30 a.m. ET. The conference will be held at the Lotte New York Palace Hotel in New York City.

A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company's website after the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of innovative RNA interference (RNAi)-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. The Company is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170208005240/en/>

Investors:

Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

or

Media:

SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media